Famotidine: Nursing Drug Guide, Renal Dosing & NCLEX Review
On the unit, the highest-stakes famotidine errors are continuing full adult doses when creatinine clearance falls below 60 mL/min—accumulation can trigger CNS toxicity (confusion, delirium, seizures) and QT prolongation, especially when duplicate PPI plus H2 therapy or tizanidine co-therapy is missed on reconciliation.
PEPCID labeling warns that central nervous system adverse reactions—including confusion, delirium, hallucinations, disorientation, agitation, seizures, and lethargy—occur in elderly patients and in patients with moderate and severe renal impairment when famotidine is not dose-reduced. QT prolongation has also been reported in renal impairment. When creatinine clearance is less than 60 mL/min, use Table 2 maximum doses by indication—giving standard 40 mg twice-daily regimens to a patient with CKD can cause preventable neurotoxicity. Verify CrCl or eGFR, reconcile duplicate acid-suppression orders, and screen for tizanidine co-therapy before every dose.
📋 Contents
⚡ Quick facts
💡 Key takeaway
When creatinine clearance is below 60 mL/min, reduce famotidine to Table 2 maximums—continuing 40 mg twice daily in moderate CKD can cause confusion, delirium, or seizures. Reconcile duplicate PPI plus H2 orders, verify tizanidine interactions, and trend creatinine on every pass.
Most common brand names
Famotidine is widely stocked as generic tablets and as the reference brand Pepcid (PEPCID 20 mg and 40 mg tablets per DailyMed). Verify strength and formulation—20 mg and 40 mg tablets are not suitable for every pediatric weight band because the lowest tablet strength may exceed recommended pediatric doses.
Do not confuse famotidine with other acid-suppressing agents such as omeprazole or cimetidine on the MAR. Many patients arrive on both a proton pump inhibitor and an H2 blocker after admission unless orders are reconciled.
Why we give it — Indications
Famotidine is a histamine H2-receptor antagonist used to suppress gastric acid secretion. Nurses administer it for acid-mediated upper GI conditions; symptomatic relief does not exclude gastric malignancy—follow prescriber plans for diagnostic follow-up when alarm symptoms persist.
| Use | Detail |
|---|---|
| GERD / symptomatic nonerosive reflux | 20 mg twice daily for up to 6 weeks in adults with normal renal function per PEPCID labeling. Reduce maximum dose when creatinine clearance is less than 60 mL/min. |
| Active peptic ulcer (duodenal or gastric) | Duodenal ulcer: 40 mg once daily or 20 mg twice daily up to 8 weeks. Gastric ulcer: 40 mg once daily up to 8 weeks. Renal maximums apply in CKD. |
| Erosive esophagitis | 20 mg twice daily or 40 mg twice daily for up to 12 weeks when diagnosed by endoscopy—use Table 2 caps in moderate to severe renal impairment. |
| Gastritis / dyspepsia (prescriber-directed) | Off-label or symptom-directed use may appear on MARs—still apply renal dose rules and avoid duplicate acid suppression without intent. |
| Pathological hypersecretory conditions | Starting dosage 20 mg every 6 hours, individualized up to 160 mg every 6 hours in normal renal function—avoid use in moderate to severe renal impairment per labeling when doses may exceed evaluated maximums. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Famotidine competitively inhibits histamine H2 receptors on gastric parietal cells, reducing basal and stimulated acid secretion. After oral dosing, antisecretory effect begins within about one hour, with dose-related maximal effect over one to three hours and duration of roughly 10–12 hours for standard doses per PEPCID clinical pharmacology. Because famotidine is substantially renally eliminated, drug accumulation in CKD raises serum levels and CNS exposure unless the dose is reduced.
Dosing overview
Adult dosing depends on indication and renal function. PEPCID Table 1 lists standard doses for patients with creatinine clearance 60 mL/min or greater. Table 2 lists maximum doses when CrCl is 30–60 or less than 30 mL/min—always use the lowest effective dose and involve pharmacy when tablet strengths cannot deliver required reduced doses (alternate formulations may be needed for 10 mg regimens).
Missed dose: Take when remembered unless the next scheduled dose is near—do not double doses. For twice-daily regimens, typical scheduling is morning and bedtime per PEPCID administration instructions.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Onset | Antisecretory effect within about 1 hour of oral dosing per PEPCID labeling | Symptomatic heartburn relief may lag behind acid suppression—reassess over days |
| Peak effect | Maximum effect within 1–3 hours; dose-related | Do not expect full symptom resolution after a single dose in erosive disease |
| Duration | 10–12 hours inhibition for 20–40 mg doses in adult studies | Twice-daily regimens cover daytime and nocturnal acid; missed doses matter |
| Half-life | 2.5–3.5 hours in adults with normal renal function | Half-life lengthens indirectly via accumulation when CrCl falls—CNS toxicity may appear after several days of unadjusted dosing |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Confirm indication, dose, frequency, and that the ordered dose matches renal function (CrCl/eGFR) using PEPCID Table 2 when CrCl <60 mL/min
- Review allergy history; screen MAR and home list for duplicate PPI plus H2 blocker and for tizanidine co-therapy
- Perform medication reconciliation at admission and transfers—outpatient famotidine often continues unchanged when creatinine has declined
Contraindications
- Known hypersensitivity to famotidine or formulation components (may include anaphylaxis, angioedema, urticaria, and other serious reactions per labeling)
- No absolute contraindication for renal impairment—instead, mandatory dose reduction when CrCl is less than 60 mL/min
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Tizanidine | Famotidine may substantially increase tizanidine levels (weak CYP1A2 inhibition)—hypotension, bradycardia, excessive drowsiness | Avoid concomitant use when possible; if necessary, monitor blood pressure, heart rate, and sedation; notify pharmacist |
| Ketoconazole / itraconazole | Reduced absorption of azole antifungals when gastric pH rises | Flag chart; follow azole prescribing information for timing relative to acid suppression |
| Atazanavir, rilpivirine, ledipasvir/sofosbuvir, nilotinib, erlotinib | Drugs dependent on gastric pH for absorption may lose efficacy with H2 blockers | Verify HIV/oncology regimens with pharmacist before starting or continuing famotidine |
| Probenecid | May increase famotidine serum concentrations via OAT inhibition per labeling | Monitor for CNS adverse effects if co-administered; notify pharmacist |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral tablet or oral suspension. PEPCID may be taken with or without food; antacids may be given concomitantly per labeling.
- Typical timing: once daily at bedtime or twice daily (morning and bedtime) depending on indication
- Tablets may be swallowed whole; follow institutional protocol for crushing only when pharmacy approves
- For enteral tubes, use pharmacy-approved preparation of oral suspension or alternate formulation when tablet strength exceeds renal-adjusted dose
A patient with CrCl near 38 mL/min should not receive standard 40 mg twice-daily famotidine for symptomatic GERD—the Table 2 maximum is 20 mg once daily. Compare the MAR to the most recent serum creatinine or calculated CrCl before administration.
Expected therapeutic response
- Decrease in heartburn, regurgitation, or epigastric discomfort when used for reflux or ulcer symptoms
- Healing of erosive esophagitis or ulcer disease documented by endoscopy or prescriber assessment—not assessed at the bedside alone
- Absence of new alarm symptoms (dysphagia, GI bleeding, unintentional weight loss) despite acid suppression
- No new confusion, agitation, or sedation after dose initiation—mental status should remain stable when renal dosing is correct
Red flags — Stop and act
Stop famotidine and escalate when neurotoxicity, cardiac conduction concerns, or serious hypersensitivity are suspected—especially in elderly patients and those with CKD receiving unadjusted doses.
- New or worsening confusion, delirium, hallucinations, agitation, or seizures—consider famotidine accumulation in renal impairment
- Palpitations, syncope, or dizziness suggesting QT prolongation or arrhythmia in moderate to severe renal impairment
- Rising creatinine or oliguria suggesting acute kidney injury—reassess all nephrotoxic and renally cleared drugs
- Severe rash, angioedema, bronchospasm, or anaphylaxis—discontinue and initiate emergency pathway per protocol
- Abdominal pain, dysphagia, GI bleeding, or weight loss despite therapy—may signal gastric malignancy or complication requiring diagnostic evaluation
- Excessive sedation, hypotension, or bradycardia when famotidine is combined with tizanidine
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Headache, diarrhea, constipation, abdominal pain | Common in clinical trials per PEPCID Section 6.1 | Document and trend; evaluate persistent GI symptoms for alternate causes |
| CNS reactions (confusion, delirium, hallucinations, agitation, seizures, lethargy) | Serious; reported in elderly and in moderate/severe renal impairment per Warnings | Hold famotidine; notify prescriber; verify renal dose; monitor mental status and fall risk |
| QT prolongation, arrhythmia, AV block | Reported in renal impairment per labeling | Monitor cardiac symptoms; obtain ECG per prescriber; ensure renal-adjusted dosing |
| Hypersensitivity (anaphylaxis, angioedema, bronchospasm, urticaria) | Serious; potentially fatal | Discontinue immediately; emergency response per protocol |
| Gynecomastia, libido decrease, impotence | Reported postmarketing | Document; discuss with prescriber if persistent or distressing |
| Elevated liver enzymes, hepatitis | Rare postmarketing reports | Monitor for jaundice or right upper quadrant pain; notify prescriber |
On a small screen, swipe or scroll sideways to see the full table.
Common adverse reactions reflect PEPCID Section 6.1; CNS and QT warnings are emphasized in Section 5.1 and Use in Specific Populations (8.5, 8.6).
Overdose, toxicity, and antidote
Overdosage adverse reactions are similar to those seen at recommended doses per PEPCID overdosage section. In renal impairment, standard doses may produce toxicity through accumulation rather than a single massive ingestion.
Management
- No specific antidote described in PEPCID labeling
- Treatment is symptomatic and supportive; remove unabsorbed material from the GI tract when appropriate
- Monitor mental status, vital signs, and ECG when CNS or cardiac symptoms are present
- Hemodialysis may eliminate famotidine because of low protein binding—limited clinical experience
Contact local poison control or medical toxicology services for over-exposure guidance per facility protocol and local emergency guidance.
Look-alike / sound-alike and error prevention
- Famotidine vs cimetidine vs nizatidine—all H2 blockers with different drug-interaction profiles; verify correct drug on MAR
- Famotidine vs PPIs (omeprazole, pantoprazole)—duplicate acid suppression is common after admission; reconcile home and inpatient orders
- Pepcid vs Pepcid Complete—combination products include antacids; not interchangeable with plain famotidine tablets
- Dose strength mix-ups—20 mg vs 40 mg tablets; renal-adjusted orders may require pharmacy reformulation when 10 mg is needed
- Continuing outpatient BID dosing when creatinine rises—automatic reordering without CrCl review is a high-risk workflow failure
- IV famotidine vs oral—when IV is discontinued, ensure oral dose is renal-adjusted, not copied from pre-CKD orders
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Food timing | May take with or without food per PEPCID; antacids allowed—still verify renal dose before giving |
| Renal check | Before each dose in CKD: compare MAR dose to Table 2 using latest creatinine/CrCl—do not rely on admission weight alone |
| Mental status | Baseline orientation on start; daily confusion screen in elderly and CrCl <60—hold and notify if acute change |
| Duplicate therapy | Scan MAR for PPI plus famotidine; stop redundant agent per pharmacist/prescriber |
| Tizanidine pair | Flag combination; monitor BP, HR, and sedation each shift |
| Commonly missed | Home OTC famotidine, unchanged BID dose after AKI, and omeprazole plus famotidine overlap |
| Ask pharmacy when | CrCl <30 needing 10 mg daily, tube administration, pH-dependent oncology/HIV drugs, or formulation change after renal decline |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Chronic kidney disease (CrCl <60 mL/min) | Mandatory dose reduction per PEPCID Table 2; AUC increases at least 2-fold (CrCl 30–60) and 5-fold (CrCl <30). Monitor for confusion, QT prolongation, and sedation. |
| Elderly patients | Substantially renally excreted; use lowest effective dose and monitor renal function. Postmarketing CNS adverse reactions reported with and without documented renal impairment. |
| Acute kidney injury / rising creatinine | Hold or reduce dose when creatinine jumps—outpatient famotidine orders often remain unchanged unless pharmacy re-verifies. |
| Patients on tizanidine | Avoid combination when possible; monitor for hypotension, bradycardia, and excessive drowsiness if co-administered. |
| Pregnancy | Available human data insufficient to establish drug-associated risk per labeling; animal studies at high doses showed adverse developmental effects. Use only if clearly needed per prescriber. |
| Lactation | Limited published literature suggests famotidine may be present in human milk. Weigh breastfeeding benefits against clinical need and potential infant exposure. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Renal function—trend basic metabolic panel and calculated CrCl; adjust dose when creatinine clearance falls below 60 mL/min
- Mental status—orientation, agitation, hallucinations, or new sedation in elderly and CKD patients
- Cardiac symptoms—palpitations, syncope, or irregular pulse when QT prolongation is a concern in renal impairment
- GI symptoms—heartburn relief, abdominal discomfort, and stool pattern
- Blood pressure and heart rate when tizanidine is co-administered
Document
- Dose, route, time, and renal function value used to verify the dose
- Indication, planned duration, and pharmacy review when CrCl changes
- Patient education on reporting confusion, dizziness, or excessive sleepiness
- Medication reconciliation notes when duplicate PPI/H2 therapy is stopped
Patient teaching
- Take famotidine exactly as prescribed—kidney disease may require a lower dose than you used at home
- Report sudden confusion, agitation, unusual dreams, seizures, or extreme drowsiness immediately
- Report palpitations, fainting, or dizziness—these may relate to QT changes in kidney disease
- Tell your care team about all medicines, including OTC acid reducers, muscle relaxants, and antifungals
- Do not double doses; if a dose is missed, take when remembered unless the next dose is soon
- Seek urgent care for severe rash, facial swelling, or trouble breathing
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Known hypersensitivity to famotidine or formulation components
- Ordered dose exceeds PEPCID Table 2 maximum for the patient’s current creatinine clearance
- New confusion, delirium, agitation, hallucinations, or seizure—hold and evaluate for famotidine-related CNS toxicity
- New significant QT or arrhythmia symptoms in a patient with renal impairment on famotidine
- Duplicate PPI plus H2 blocker without prescriber intent, or tizanidine co-therapy with excessive sedation or hypotension
- Creatinine rising acutely—reassess dose before giving scheduled famotidine
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Famotidine passes look routine, but renal dose failures and interaction gaps cause preventable harm: CNS toxicity in CKD, QT symptoms in accumulation, and tizanidine oversedation when pharmacy review is skipped at admission.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, time—and renal-adjusted dose verified against latest CrCl
- Screen for duplicate omeprazole/PPI plus famotidine on MAR and home list
- Check tizanidine and pH-dependent medications (azole antifungals, selected antiretrovirals/oncology drugs)
- Baseline and current mental status documented in elderly and CKD patients
2. High-alert and safety badge
Not a traditional high-alert medication—renal CNS focusFamotidine is not universally listed as a high-alert drug, but unadjusted dosing in moderate to severe renal impairment can cause serious CNS and cardiac adverse reactions. Treat renal dose errors with the same urgency as high-alert checks.
3. Clinical workflow: hold and question rules
- If creatinine clearance is 38 mL/min and the MAR still shows famotidine 40 mg BID, hold and request pharmacy verification before administration
- If a patient on tizanidine becomes hypotensive or excessively sedated after famotidine is added, hold and notify the team
- Stop and clarify when both a PPI and famotidine are active without documented indication for dual therapy
4. Critical teach-back questions
- “Did your doctor change your stomach medicine dose because of kidney function?” (Renal adjustment may be required when creatinine rises.)
- “What new thinking or mood changes should you report?” (Confusion, agitation, hallucinations, or extreme sleepiness.)
5. Care coordination
Pharmacist: Renal dose verification, tizanidine interaction review, duplicate acid-suppression reconciliation, and formulation changes when 10 mg doses are needed
Prescriber / nephrology: Worsening creatinine, persistent CNS symptoms despite dose hold, or need for alternative acid suppression in CKD
🧠 Quick mental checklist
- What is the patient’s current creatinine clearance—and does the MAR dose match Table 2?
- Any new confusion, agitation, or sedation since famotidine started or dose last changed?
- Are two acid suppressants active (PPI plus famotidine)?
- Is tizanidine on the profile—and how are BP, HR, and alertness today?
- Was renal function rechecked after AKI or contrast exposure?
Famotidine NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for famotidine with a tabbed med-surg case (MAR, labs, history, nursing notes), then priority action, cue recognition (SATA), renal trend interpretation, renal-dose cloze, ordered response steps, and matrix urgency sorting—recognise cues → analyse → prioritise → act → evaluate outcomes when confusion persists despite holding the supratherapeutic dose.
Select a tab to view MAR, labs, history, and nursing note details for this case.
- Famotidine 40 mg PO BID — continued from outpatient regimen; 0800 dose given
- Omeprazole 20 mg PO daily — added on admission day 2 for GERD flare; both remain active
- Tizanidine 4 mg PO at bedtime — for chronic back spasm
- 0900: famotidine 40 mg due; pharmacy renal-dose verification flagged but not yet resolved
- Admission BMP: creatinine 1.4 mg/dL; eGFR ~42 mL/min/1.73 m²; calculated CrCl ~38 mL/min
- Today (hospital day 4): creatinine 1.6 mg/dL (↑ from 1.4); potassium 4.8 mEq/L; magnesium 2.0 mg/dL
- QTc 462 ms on prior ECG (baseline 440 ms)—no new ECG today
- 78-year-old with stage 3b CKD and hypertension admitted for dehydration and GERD exacerbation
- Home famotidine 40 mg BID started six months ago—never adjusted after creatinine rose
- Indication on chart: symptomatic nonerosive GERD
- Lives alone; daughter reports one episode of nighttime disorientation last week at home
- 0700: Patient oriented ×2; reports vivid dreams overnight
- 1030: Attempted to climb out of bed calling for deceased spouse; sitter ordered
- 1130: BP 108/62, HR 58; patient very drowsy after tizanidine at 2200 last night
- 1200: Nurse notes outpatient famotidine dose never changed despite CKD on admission problem list
Answer key & rationale
Frequently asked questions
When should famotidine dose be reduced for renal impairment?
PEPCID prescribing information recommends dosage adjustment when creatinine clearance is less than 60 mL/min. For symptomatic nonerosive GERD with CrCl 30–60 mL/min, the maximum dose is 20 mg once daily; with CrCl below 30 mL/min, 20 mg every other day (alternate 10 mg regimens may require a different formulation).
Why can famotidine cause confusion in older adults with CKD?
Famotidine is substantially renally excreted. PEPCID labeling reports CNS adverse reactions—including confusion, delirium, hallucinations, agitation, and seizures—in elderly patients and in moderate to severe renal impairment when doses are not reduced. Hold the drug and notify the team when acute mental status changes occur.
When should a nurse hold famotidine?
Hold for hypersensitivity, doses exceeding renal maximums, new confusion or seizures suspected to be drug-related, QT or arrhythmia symptoms in renal impairment, duplicate PPI plus H2 therapy without intent, or tizanidine co-therapy with hypotension or excessive sedation.
Can famotidine be taken with food?
PEPCID may be taken with or without food per prescribing information. Antacids may be given concomitantly. Renal dose verification remains mandatory regardless of meal timing.
Why should famotidine be avoided with tizanidine when possible?
Famotidine may substantially increase tizanidine blood concentrations through CYP1A2 inhibition, causing hypotension, bradycardia, or excessive drowsiness per PEPCID labeling. Avoid the combination when possible and monitor closely if both are required.
Is there an antidote for famotidine overdose?
No specific antidote is described in PEPCID overdosage labeling. Treatment is symptomatic and supportive; hemodialysis may eliminate famotidine because of low protein binding. Contact local poison control or toxicology services per facility protocol for over-exposure.
References
-
U.S. National Library of Medicine. PEPCID (famotidine) tablets — Full prescribing information. DailyMed; revised November 2023.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a06502d9-7903-4f37-833e-e5763d502def
-
U.S. Food and Drug Administration. PEPCID (famotidine) tablets — FDA-approved product labeling (PDF).https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setId=a06502d9-7903-4f37-833e-e5763d502def
-
Hsu A, et al. StatPearls: Famotidine. Treasure Island (FL): StatPearls Publishing; updated 2023.https://www.ncbi.nlm.nih.gov/books/NBK534778/
-
National Institute for Health and Care Excellence (NICE). Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (CG184).https://www.nice.org.uk/guidance/cg184
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.